Department of Surgery, Ito Hospital, 4-3-6, Jingumae, Shibuya-ku, Tokyo, 150-8308, Japan.
Department of Surgery, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawaku, Yokohama City, Kanagawa, Japan.
Endocrine. 2020 Oct;70(1):115-122. doi: 10.1007/s12020-020-02313-5. Epub 2020 Apr 19.
Studies have shown that inflammatory biomarkers, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), are associated with prognosis or treatment efficacy in various cancers. The present study investigated the association between the inflammatory biomarkers and dynamics of NLR, and prognosis or disease progression in anaplastic thyroid carcinoma (ATC).
This study included 55 patients with ATC who had available complete blood count (CBC) data. Overall survival based on inflammatory biomarker value, and the dynamics of NLR among patients with ATC were investigated. Change in NLR was obtained by subtracting the baseline value from the max value obtained during follow-up period, and we subclassified 51 ATC patients who had follow-up CBC data into the increased group (change of NLR > 5.5) and non-increased group (change of NLR ≤ 5.5).
There were no significant differences in OS according to baseline NLR, PLR, and LMR values. Among the 51 patients with ATC who had follow-up CBC data, the median OS was 7.7 [95% confidence interval (CI): 5.2-12.1] months in the increased group (n = 27), versus 23.5 [95% CI: 13.9-not available] months in the non-increased (n = 24) group (p < 0.001).
The present study found no association between baseline inflammatory biomarkers and OS among patients with ATC. However, ATC patients whose NLR increased compared with individual baseline during follow-up period had worse prognosis than non-increased patients.
研究表明,中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)和淋巴细胞与单核细胞比值(LMR)等炎症生物标志物与各种癌症的预后或治疗效果相关。本研究旨在探讨炎症生物标志物与间变性甲状腺癌(ATC)患者 NLR 动态变化与预后或疾病进展的关系。
本研究纳入了 55 例 ATC 患者,这些患者均具有完整的全血细胞计数(CBC)数据。根据炎症生物标志物值评估总生存率,同时研究 ATC 患者 NLR 的动态变化。NLR 的变化值通过从随访期间获得的最大值中减去基线值来获得,我们将 51 例具有随访 CBC 数据的 ATC 患者分为增加组(NLR 变化>5.5)和未增加组(NLR 变化≤5.5)。
基线 NLR、PLR 和 LMR 值与 OS 无显著差异。在具有随访 CBC 数据的 51 例 ATC 患者中,增加组(n=27)的中位 OS 为 7.7 个月(95%CI:5.2-12.1),而非增加组(n=24)的中位 OS 为 23.5 个月(95%CI:13.9-未提供)(p<0.001)。
本研究发现 ATC 患者基线炎症生物标志物与 OS 之间无相关性。然而,与基线相比,在随访期间 NLR 增加的 ATC 患者预后比未增加的患者差。